tumor protein p53(TP53) Homo sapiens This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013]
Catalog No
A7180
Reactivity
Human, Rat
Applications
WB, IHC-p, IP, IF/ICC, ELISA
Modification
Phospho Specific
Source
Polyclonal Rabbit
Dilution
Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunoprecipitation: 2-5 ug/mg lysate. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/10000. Not yet tested in other applications.
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Western blot analysis of lysates from HeLa cells treated with HU, using p53 (Phospho-Ser15) Antibody. The lane on the right is blocked with the phospho peptide.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using p53 (Phospho-Ser15) Antibody. The picture on the right is blocked with the phospho peptide.
Immunohistochemical analysis of paraffin-embedded Mouse-spleen tissue. 1,p53 (phospho Ser15) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.
Immunohistochemical analysis of paraffin-embedded Mouse-lung tissue. 1,p53 (phospho Ser15) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.
Immunohistochemical analysis of paraffin-embedded Rat-spleen tissue. 1,p53 (phospho Ser15) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.
Immunohistochemical analysis of paraffin-embedded Rat-lung tissue. 1,p53 (phospho Ser15) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.
Immunohistochemical analysis of paraffin-embedded Human-lung-cancer tissue. 1,p53 (phospho Ser15) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.
Immunohistochemical analysis of paraffin-embedded Human-lung tissue. 1,p53 (phospho Ser15) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.
Immunohistochemical analysis of paraffin-embedded Human-colon tissue. 1,p53 (phospho Ser15) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.
Tang, Hailong, et al. "Low dose dinaciclib enhances doxorubicin‑induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways." Oncology letters 16.5 (2018): 6608-6614.